Special Drug Use Investigation (Retrospective) for Arixtra (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg).

Trial Profile

Special Drug Use Investigation (Retrospective) for Arixtra (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 25 Jul 2014 Planned End Date changed from 1 Jul 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 14 Jun 2013 Planned End Date changed from 1 Oct 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top